GlobeNewswire Inc | Nov 3, 2020 07:00AM EST

November 03, 2020

CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.(Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its third quarter 2020 financial results will be released on Tuesday, November 10, 2020 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Dial-in NumberU.S./Canada Dial-in Number: 800-527-6973International Dial-in Number: 470-495-9162Conference ID: 2408316

Replay Dial-in Number: 855-859-2056Replay International Dial-in Number: 404-537-3406Conference ID: 2408316

An audio webcast will be accessible through the Investor Relations section of the companys website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.

About Fulcrum TherapeuticsFulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrums proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and Phase 3 for the treatment of COVID-19. Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.

Please visit www.fulcrumtx.com.

Contact:Christi WaarichDirector, Investor Relations andCorporate Communications 617-651-8664cwaarich@fulcrumtx.com